BioXcel Historical Financial Ratios

BTAI Stock

USD 2.14 0.17 7.36%

BioXcel Therapeutics is presently reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 20.52 or Invested Capital of 0.0 will help investors to properly organize and evaluate BioXcel Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

About BioXcel Financial Ratios Analysis

BioXcel TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate BioXcel Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on BioXcel financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across BioXcel Therapeutics history.

BioXcel Therapeutics Financial Ratios Chart

As of now, BioXcel Therapeutics' Interest Debt Per Share is increasing as compared to previous years. The BioXcel Therapeutics' current Debt To Assets is estimated to increase to 1.30, while PTB Ratio is projected to decrease to (22.99).

Price To Sales Ratio Days Sales Outstanding Ev To Sales Inventory Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing BioXcel Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on BioXcel Therapeutics sales, a figure that is much harder to manipulate than other BioXcel Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from BioXcel Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into BioXcel Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.As of now, BioXcel Therapeutics' Interest Debt Per Share is increasing as compared to previous years. The BioXcel Therapeutics' current Debt To Assets is estimated to increase to 1.30, while PTB Ratio is projected to decrease to (22.99).

	2023	2024	2025 (projected)
Payables Turnover	0.0923	0.0831	0.0872
Days Of Inventory On Hand	576.76	663.27	630.11

Payables Turnover Days Of Inventory On Hand

BioXcel Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.45	1.0	0.45	0.99	0.79	0.72	-0.45	1.0	0.79	0.67	-1.0	0.76	1.0	-0.85	1.0	-0.03	-0.41	-0.8	-0.36	-0.41	0.6	-0.34	0.0	-0.5	-0.42
Ptb Ratio	-0.45		-0.45	0.37	-0.52	-0.78	-0.72	1.0	-0.45	-0.79	-0.92	0.45	-0.8	-0.45	0.69	-0.45	0.71	0.92	0.33	-0.29	0.92	-0.83	0.86	-0.86	0.99	0.93
Days Sales Outstanding	1.0	-0.45		0.45	0.99	0.79	0.72	-0.45	1.0	0.79	0.67	-1.0	0.76	1.0	-0.85	1.0	-0.03	-0.41	-0.8	-0.36	-0.41	0.6	-0.34	0.0	-0.5	-0.42
Book Value Per Share	0.45	0.37	0.45		0.4	-0.04	-0.16	0.37	0.45	-0.05	-0.19	-0.45	-0.09	0.45	0.04	0.45	0.83	0.31	-0.48	-0.13	0.31	-0.29	0.42	-0.63	0.34	0.31
Free Cash Flow Yield	0.99	-0.52	0.99	0.4		0.84	0.76	-0.52	0.99	0.84	0.74	-0.99	0.81	0.99	-0.86	0.99	-0.1	-0.48	-0.81	-0.32	-0.48	0.65	-0.41	0.09	-0.58	-0.49
Operating Cash Flow Per Share	0.79	-0.78	0.79	-0.04	0.84		0.97	-0.78	0.79	1.0	0.91	-0.79	1.0	0.79	-0.85	0.79	-0.57	-0.7	-0.78	-0.31	-0.7	0.93	-0.72	0.52	-0.83	-0.72
Capex To Depreciation	0.72	-0.72	0.72	-0.16	0.76	0.97		-0.72	0.72	0.97	0.83	-0.72	0.97	0.72	-0.82	0.72	-0.66	-0.64	-0.75	-0.45	-0.64	0.92	-0.67	0.48	-0.76	-0.66
Pb Ratio	-0.45	1.0	-0.45	0.37	-0.52	-0.78	-0.72		-0.45	-0.79	-0.92	0.45	-0.8	-0.45	0.69	-0.45	0.71	0.92	0.33	-0.29	0.92	-0.83	0.86	-0.86	0.99	0.93
Ev To Sales	1.0	-0.45	1.0	0.45	0.99	0.79	0.72	-0.45		0.79	0.67	-1.0	0.76	1.0	-0.85	1.0	-0.03	-0.41	-0.8	-0.36	-0.41	0.6	-0.34	0.0	-0.5	-0.42
Free Cash Flow Per Share	0.79	-0.79	0.79	-0.05	0.84	1.0	0.97	-0.79	0.79		0.91	-0.79	1.0	0.79	-0.85	0.79	-0.57	-0.71	-0.77	-0.3	-0.71	0.93	-0.72	0.53	-0.83	-0.72
Roic	0.67	-0.92	0.67	-0.19	0.74	0.91	0.83	-0.92	0.67	0.91		-0.67	0.91	0.67	-0.84	0.67	-0.63	-0.82	-0.52	0.02	-0.82	0.9	-0.85	0.73	-0.96	-0.83
Inventory Turnover	-1.0	0.45	-1.0	-0.45	-0.99	-0.79	-0.72	0.45	-1.0	-0.79	-0.67		-0.76	-1.0	0.85	-1.0	0.04	0.41	0.8	0.35	0.41	-0.6	0.35	0.0	0.5	0.42
Net Income Per Share	0.76	-0.8	0.76	-0.09	0.81	1.0	0.97	-0.8	0.76	1.0	0.91	-0.76		0.76	-0.84	0.76	-0.61	-0.72	-0.76	-0.3	-0.72	0.94	-0.73	0.56	-0.84	-0.74
Days Of Inventory On Hand	1.0	-0.45	1.0	0.45	0.99	0.79	0.72	-0.45	1.0	0.79	0.67	-1.0	0.76		-0.85	1.0	-0.03	-0.41	-0.8	-0.36	-0.41	0.6	-0.34	0.0	-0.5	-0.42
Payables Turnover	-0.85	0.69	-0.85	0.04	-0.86	-0.85	-0.82	0.69	-0.85	-0.85	-0.84	0.85	-0.84	-0.85		-0.85	0.44	0.62	0.54	0.23	0.62	-0.82	0.61	-0.33	0.73	0.63
Capex To Revenue	1.0	-0.45	1.0	0.45	0.99	0.79	0.72	-0.45	1.0	0.79	0.67	-1.0	0.76	1.0	-0.85		-0.03	-0.41	-0.8	-0.36	-0.41	0.6	-0.34	0.0	-0.5	-0.42
Cash Per Share	-0.03	0.71	-0.03	0.83	-0.1	-0.57	-0.66	0.71	-0.03	-0.57	-0.63	0.04	-0.61	-0.03	0.44	-0.03		0.62	0.06	0.09	0.62	-0.73	0.69	-0.8	0.7	0.62
Pocfratio	-0.41	0.92	-0.41	0.31	-0.48	-0.7	-0.64	0.92	-0.41	-0.71	-0.82	0.41	-0.72	-0.41	0.62	-0.41	0.62		0.3	-0.29	1.0	-0.73	0.85	-0.77	0.9	1.0
Interest Coverage	-0.8	0.33	-0.8	-0.48	-0.81	-0.78	-0.75	0.33	-0.8	-0.77	-0.52	0.8	-0.76	-0.8	0.54	-0.8	0.06	0.3		0.53	0.3	-0.57	0.27	-0.02	0.38	0.31
Capex To Operating Cash Flow	-0.36	-0.29	-0.36	-0.13	-0.32	-0.31	-0.45	-0.29	-0.36	-0.3	0.02	0.35	-0.3	-0.36	0.23	-0.36	0.09	-0.29	0.53		-0.29	-0.19	-0.14	0.38	-0.21	-0.29
Pfcf Ratio	-0.41	0.92	-0.41	0.31	-0.48	-0.7	-0.64	0.92	-0.41	-0.71	-0.82	0.41	-0.72	-0.41	0.62	-0.41	0.62	1.0	0.3	-0.29		-0.73	0.85	-0.77	0.9	1.0
Days Payables Outstanding	0.6	-0.83	0.6	-0.29	0.65	0.93	0.92	-0.83	0.6	0.93	0.9	-0.6	0.94	0.6	-0.82	0.6	-0.73	-0.73	-0.57	-0.19	-0.73		-0.82	0.68	-0.86	-0.75
Income Quality	-0.34	0.86	-0.34	0.42	-0.41	-0.72	-0.67	0.86	-0.34	-0.72	-0.85	0.35	-0.73	-0.34	0.61	-0.34	0.69	0.85	0.27	-0.14	0.85	-0.82		-0.84	0.87	0.85
Roe	0.0	-0.86	0.0	-0.63	0.09	0.52	0.48	-0.86	0.0	0.53	0.73	0.0	0.56	0.0	-0.33	0.0	-0.8	-0.77	-0.02	0.38	-0.77	0.68	-0.84		-0.85	-0.78
Ev To Operating Cash Flow	-0.5	0.99	-0.5	0.34	-0.58	-0.83	-0.76	0.99	-0.5	-0.83	-0.96	0.5	-0.84	-0.5	0.73	-0.5	0.7	0.9	0.38	-0.21	0.9	-0.86	0.87	-0.85		0.91
Pe Ratio	-0.42	0.93	-0.42	0.31	-0.49	-0.72	-0.66	0.93	-0.42	-0.72	-0.83	0.42	-0.74	-0.42	0.63	-0.42	0.62	1.0	0.31	-0.29	1.0	-0.75	0.85	-0.78	0.91

Click cells to compare fundamentals

BioXcel Therapeutics Account Relationship Matchups

BioXcel Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	77.54	38.7	125.41	(24.33)	(21.9)	(22.99)
Book Value Per Share	9.53	8.41	2.74	(1.94)	(1.75)	(1.66)
Free Cash Flow Yield	(0.004159)	(0.009628)	(0.0141)	(0.11)	(0.13)	(0.12)
Operating Cash Flow Per Share	(3.06)	(3.12)	(4.83)	(5.32)	(6.12)	(5.81)
Capex To Depreciation	1.68	1.5	0.43	0.0629	0.0723	0.0687
Pb Ratio	77.54	38.7	125.41	(24.33)	(21.9)	(22.99)
Free Cash Flow Per Share	(3.07)	(3.13)	(4.84)	(5.32)	(6.12)	(5.81)
Roic	(0.39)	(0.48)	(0.96)	(3.67)	(4.22)	(4.01)
Net Income Per Share	(3.78)	(4.04)	(6.13)	(6.15)	(7.07)	(6.72)
Payables Turnover	0.0472	0.0635	0.001955	0.0923	0.0831	0.0872
Cash Per Share	9.83	8.83	6.92	2.24	2.02	3.74
Pocfratio	(241.57)	(104.42)	(71.14)	(8.87)	(7.98)	(8.38)
Capex To Operating Cash Flow	(0.004763)	(0.005417)	(0.001027)	(1.29E-4)	(1.16E-4)	(1.22E-4)
Pfcf Ratio	(240.42)	(103.86)	(71.07)	(8.87)	(7.98)	(8.38)
Days Payables Outstanding	11.6K	7.7K	5.7K	4.0K	4.5K	4.3K
Income Quality	0.81	0.77	0.82	0.87	0.78	0.56
Roe	(0.4)	(0.48)	(2.24)	3.17	3.64	3.83
Ev To Operating Cash Flow	(238.38)	(101.6)	(70.4)	(9.1)	(8.19)	(8.6)
Pe Ratio	(195.45)	(80.45)	(56.03)	(7.68)	(6.91)	(7.26)
Return On Tangible Assets	(0.37)	(0.45)	(0.83)	(2.43)	(2.19)	(2.3)
Ev To Free Cash Flow	(237.25)	(101.06)	(70.33)	(9.1)	(8.19)	(8.6)
Earnings Yield	(0.005117)	(0.0124)	(0.0178)	(0.13)	(0.15)	(0.14)
Net Debt To E B I T D A	2.58	2.16	0.63	(0.22)	(0.25)	(0.24)
Current Ratio	18.33	13.98	6.17	2.65	2.38	2.26
Tangible Book Value Per Share	9.53	8.41	2.74	(1.94)	(1.75)	(1.66)
Shareholders Equity Per Share	9.53	8.41	2.74	(1.94)	(1.75)	(1.66)
Debt To Equity	0.00791	0.006307	1.23	(1.79)	(2.06)	(1.96)
Capex Per Share	0.0146	0.0169	0.004962	6.87E-4	7.9E-4	7.5E-4
Graham Net Net	9.22	8.16	2.35	(2.2)	(1.98)	(1.88)
Interest Debt Per Share	0.0766	0.0545	3.65	3.94	3.54	3.72
Debt To Assets	0.007434	0.005839	0.46	1.38	1.24	1.3
Enterprise Value Over E B I T D A	(192.93)	(78.01)	(60.54)	(8.53)	(7.68)	(8.06)
Price Earnings Ratio	(195.45)	(80.45)	(56.03)	(7.68)	(6.91)	(7.26)
Price Book Value Ratio	77.54	38.7	125.41	(24.33)	(21.9)	(22.99)
Price Earnings To Growth Ratio	(2.17)	(11.7)	(1.08)	(23.54)	(27.07)	(25.71)
Days Of Payables Outstanding	11.6K	7.7K	5.7K	4.0K	4.5K	4.3K
Price To Operating Cash Flows Ratio	(241.57)	(104.42)	(71.14)	(8.87)	(7.98)	(8.38)
Price To Free Cash Flows Ratio	(240.42)	(103.86)	(71.07)	(8.87)	(7.98)	(8.38)

Currently Active Assets on Macroaxis

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria
HMY	Harmony Gold Mining
FSM	Fortuna Silver Mines

When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:

How To Invest In BioXcel

Details

Is BioXcel Stock a good investment?

Details

What is BioXcel Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(34.59)

Revenue Per Share

1.019

Quarterly Revenue Growth

(0.37)

Return On Assets

(0.62)

Return On Equity

(17.67)

The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioXcel Historical Financial Ratios

About BioXcel Financial Ratios Analysis

BioXcel Therapeutics Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Inventory Turnover

BioXcel Therapeutics fundamentals Correlations

BioXcel Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioXcel Therapeutics fundamentals Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Days Sales Outstanding	+ 1.0	Price To Sales Ratio
Ev To Sales	+ 1.0	Price To Sales Ratio
Days Of Inventory On Hand	+ 1.0	Price To Sales Ratio
Capex To Revenue	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Ev To Sales	+ 1.0	Days Sales Outstanding

Capex To Revenue	- 1.0	Inventory Turnover
Days Of Inventory On Hand	- 1.0	Inventory Turnover
Inventory Turnover	- 1.0	Ev To Sales
Inventory Turnover	- 1.0	Days Sales Outstanding
Inventory Turnover	- 1.0	Price To Sales Ratio
Inventory Turnover	- 0.99	Free Cash Flow Yield